Skip to main content
Premium Trial:

Request an Annual Quote

The Little RNAs

MIT's Technology Review checks in with Regulus, a startup owned by both Alnylam and Isis that focuses on developing miRNA-based drugs. "The analogy we like to use is that miRNA is the maestro conducting the orchestra — the entire biological network," Regulus's Zak Zimmerman tells Tech Review."If something goes wrong with the maestro, the orchestra starts to play off-key." So far, the company has developed compounds that affect the oligonucleotides of miRNAs and is particularly interested in heart failure and renal fibrosis. However, the article adds, getting from a compound to a drug is likely to take a lot of work as miRNAs affect many processes and therapies targeting them may cause a variety of side effects.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.